Pilot study on the therapeutic efficacy, clinical safety, and dosage finding of enciprazine in out-patients with anxious and anxious-depressive syndromes.

Abstract

The new basic propanolamine derivative enciprazine (D 13 112) was tested in an open single-blind phase-II trial with regard to therapeutic efficacy, clinical safety, and dosage finding. The drug showed a good efficacy in mildly ill patients. Under the highest dosage frequently fatigue was reported. In 78% of the patients the enciprazine trial succeeded in shifting patients from benzodiazepines to non-benzodiazepines or in discontinuation of psychopharmacotherapy after completion of the trial.

• Authors: G Scheibe, R Grohmann, P Buchheim
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 40 Issue 6 Pg. 644-6 (Jun 1990) ISSN: 0004-4172 [Print] Germany
• PMID: 2204343 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Piperazines
• Tranquilizing Agents
• Prolactin
• enciprazine

Topics

• Adult
• Anxiety Disorders (drug therapy, psychology)
• Clinical Trials as Topic
• Depression (drug therapy, psychology)
• Female
• Humans
• Male
• Middle Aged
• Outpatients
• Pilot Projects
• Piperazines (administration & dosage, adverse effects, therapeutic use)
• Prolactin (blood)
• Psychiatric Status Rating Scales
• Single-Blind Method
• Tranquilizing Agents (administration & dosage, therapeutic use)